AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19306149 — intervention group
Group type: COMPARATOR
Intervention: Infrequent therapist contact (one e-mail per week)
Number of subjects: 57
Study 19306149 — intervention group
Group type: EXPERIMENTAL
Intervention: Both frequent and infrequent contact
Number of subjects: 57
Study 16732018 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% calorie restriction (CR)
Number of subjects: 48
Study 16732018 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5% calorie restriction + 12.5% energy expenditure through structured exercise (CREX)
Number of subjects: 48
Study 16732018 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% weight loss by a low-calorie diet (LCD) followed by weight maintenance for 6 months
Number of subjects: 48
Study 16732018 — intervention group
Group type: COMPARATOR
Intervention: Control (100% of energy requirements)
Number of subjects: 48
Study 15110928 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum leptin levels at discharge from inpatient treatment
Number of subjects: 18
Study 11061603 — intervention group
Group type: EXPERIMENTAL
Intervention: BEACOPP chemotherapy (dose-intensified variant, arm 2)
Number of subjects: 858
Study 11061603 — intervention group
Group type: COMPARATOR
Intervention: BEACOPP chemotherapy (baseline variant, arm 1)
Number of subjects: 858
Study 8884052 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased tonal auditory threshold (up to 30 dB) without decrease of the discomfort threshold
Number of subjects: 385
Study 8884052 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased discomfort threshold (with about 15‐20 dB) at increased tonal auditory threshold (up to 45 dB)
Number of subjects: 385
Study 8884052 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased discomfort threshold at increased (over 50 dB) tonal auditory threshold
Number of subjects: 385
Study 8884052 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 385
Study 1390143 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic limb ulcer therapy (PELUT) device used at home for 3 hours daily for 8 weeks as an adjunct to a wound dressing
Number of subjects: 0
Study 1390143 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic limb ulcer therapy (PELUT) device
Number of subjects: 0
Study 1390143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3890197 — intervention group
Group type: EXPERIMENTAL
Intervention: Human insulin (recombinant DNA origin)
Number of subjects: 88
Study 3890197 — intervention group
Group type: COMPARATOR
Intervention: Iletin II pork insulin
Number of subjects: 88
Study 31026438 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 96
Study 31026438 — intervention group
Group type: COMPARATOR
Intervention: Surveillance
Number of subjects: 96
Study 29221735 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital thoracic drainage system (group D)
Number of subjects: 299
Study 29221735 — intervention group
Group type: COMPARATOR
Intervention: Traditional thoracic drainage system (group T)
Number of subjects: 299
Study 29221735 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital thoracic drainage system (group D) in patients with postoperative air leak
Number of subjects: 299
Study 29221735 — intervention group
Group type: COMPARATOR
Intervention: Traditional thoracic drainage system (group T) in patients with postoperative air leak
Number of subjects: 299
Study 26868314 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional visualization (3DV) model
Number of subjects: 0
Study 26868314 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional printing (3DP) model
Number of subjects: 0
Study 26868314 — intervention group
Group type: COMPARATOR
Intervention: Traditional anatomical atlas
Number of subjects: 0
Study 24280948 — intervention group
Group type: COMPARATOR
Intervention: Sham laser (0 joules/point)
Number of subjects: 144
Study 24280948 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose laser (0.2 J/point)
Number of subjects: 144
Study 24280948 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose laser (0.8 J/point)
Number of subjects: 144
Study 22496161 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (100 mg/d)
Number of subjects: 59
Study 22496161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 20615494 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40 IU twice a day for 3 weeks)
Number of subjects: 19
Study 20615494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 17604300 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic drink containing Lactobacillus casei, L bulgaricus, and Streptococcus thermophilus, 100 g (97 ml) twice a day during antibiotics and for one week after.
Number of subjects: 135
Study 17604300 — intervention group
Group type: COMPARATOR
Intervention: Placebo group received a longlife sterile milkshake.
Number of subjects: 135
Study 17604300 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic drink containing Lactobacillus casei, L bulgaricus, and Streptococcus thermophilus.
Number of subjects: 135
Study 15685041 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavitary hyperthermia (ICHT) combined with chemotherapy (5‐FU and mitomycin‐C) and radiotherapy.
Number of subjects: 49
Study 15685041 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (5‐FU and mitomycin‐C) and radiotherapy without ICHT.
Number of subjects: 49
Study 12109823 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy plus radiotherapy
Number of subjects: 8
Study 12109823 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy without cisplatin
Number of subjects: 8
Study 9989694 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg folic acid/d
Number of subjects: 42
Study 9989694 — intervention group
Group type: COMPARATOR
Intervention: 0 mg folic acid/d (unsupplemented)
Number of subjects: 42
Study 9989694 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary folate intake
Number of subjects: 42
Study 9503043 — intervention group
Group type: COMPARATOR
Intervention: Daily supplementation with antioxidant vitamins (vitamin C, 120 mg; vitamin E, 30 mg; beta‐carotene, 6 mg) and minerals (selenium, 100 micrograms; zinc, 20 mg)
Number of subjects: 12735
Study 1756344 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesic nitrous oxide
Number of subjects: 0
Study 1756344 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Carbogen)
Number of subjects: 0
Study 1756344 — intervention group
Group type: COMPARATOR
Intervention: Placebo alone
Number of subjects: 0
Study 6357891 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaprozin (1200 mg)
Number of subjects: 105
Study 6357891 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (650 mg)
Number of subjects: 105
Study 6357891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 30420725 — intervention group
Group type: EXPERIMENTAL
Intervention: High-efficiency (HE: true-HEPA) indoor air filtration
Number of subjects: 40
Study 30420725 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-efficiency (LE: HEPA-type) indoor air filtration
Number of subjects: 40
Study 30420725 — intervention group
Group type: COMPARATOR
Intervention: No filter (control)
Number of subjects: 40
Study 29543106 — intervention group
Group type: COMPARATOR
Intervention: Light/Moderate Walking (prepregnancy)
Number of subjects: 3687
Study 29543106 — intervention group
Group type: COMPARATOR
Intervention: Light/Moderate Walking (early pregnancy)
Number of subjects: 3687
Study 29543106 — intervention group
Group type: COMPARATOR
Intervention: Yoga Practice
Number of subjects: 3687
Study 29543106 — intervention group
Group type: EXPERIMENTAL
Intervention: No Light/Moderate Walking
Number of subjects: 3687
Study 27007256 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled psychological support
Number of subjects: 77
Study 27007256 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-scheduled psychological support
Number of subjects: 77
Study 27007256 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 77
Study 24885267 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral nerve block (0.5 mls/kg 0.25% levo‐bupivacaine) followed by ropivacaine (0.2% 5 ml/hr‐1) infused via a femoral nerve catheter until 48 hours post‐surgery
Number of subjects: 150
Study 24885267 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 150
Study 24885267 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral nerve block
Number of subjects: 150
Study 22632142 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioners (GPs) managing CVADs in the community
Number of subjects: 50
Study 22632142 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for using CVADs
Number of subjects: 50
Study 22632142 — intervention group
Group type: EXPERIMENTAL
Intervention: Education in CVAD management
Number of subjects: 50
Study 22632142 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of existing guidelines
Number of subjects: 50
Study 22632142 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary responsibility for care of CVADs
Number of subjects: 50
Study 22632142 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenges identified by GPs
Number of subjects: 50
Study 22632142 — intervention group
Group type: EXPERIMENTAL
Intervention: Suggestions to address challenges
Number of subjects: 50
Study 20980590 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 0
Study 20980590 — intervention group
Group type: EXPERIMENTAL
Intervention: Satiety (prescan meal)
Number of subjects: 0
Study 18411608 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy extracorporeal shock wave therapy (ESWT)
Number of subjects: 25
Study 18411608 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 25
Study 15834740 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine and silver-sulfadiazine (CHSS) coated catheters
Number of subjects: 184
Study 15834740 — intervention group
Group type: COMPARATOR
Intervention: Control catheters (uncoated)
Number of subjects: 184
Study 12616982 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 17 beta-oestradiol daily for 6 weeks
Number of subjects: 0
Study 12616982 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study 10518081 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone treatment (4 IU/m(2)/d, 6 IU/m(2)/d, 8 IU/m(2)/d)
Number of subjects: 68
Study 10518081 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone treatment
Number of subjects: 68
Study 7793204 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil 10 micrograms.kg‐1 (Group B)
Number of subjects: 40
Study 7793204 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Group A)
Number of subjects: 40
Study 1958603 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% lidocaine plus 1 mg butorphanol plus 1:300,000 epinephrine
Number of subjects: 50
Study 1958603 — intervention group
Group type: COMPARATOR
Intervention: 1.5% lidocaine plus 1:300,000 epinephrine
Number of subjects: 50
Study 7216122 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 315
Study 7216122 — intervention group
Group type: COMPARATOR
Intervention: Glucose
Number of subjects: 315
Study 30259799 — intervention group
Group type: EXPERIMENTAL
Intervention: Employed individuals
Number of subjects: 1000
Study 30259799 — intervention group
Group type: COMPARATOR
Intervention: Unemployed individuals
Number of subjects: 1000
Study 30450593 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinus Crestal Approach (SCA) drill kit technique
Number of subjects: 12
Study 30450593 — intervention group
Group type: COMPARATOR
Intervention: Conventional osteotome technique
Number of subjects: 12
Study 27352623 — intervention group
Group type: EXPERIMENTAL
Intervention: NIAT-rituximab (375 mg/m2 intravenous rituximab on days 1 and 8)
Number of subjects: 75
Study 27352623 — intervention group
Group type: COMPARATOR
Intervention: NIAT alone
Number of subjects: 75
Study 27352623 — intervention group
Group type: EXPERIMENTAL
Intervention: NIAT-rituximab
Number of subjects: 75
Study 27352623 — intervention group
Group type: COMPARATOR
Intervention: NIAT
Number of subjects: 75
Study 25599299 — intervention group
Group type: EXPERIMENTAL
Intervention: Emla with suggestions of analgesia
Number of subjects: 142
Study 25599299 — intervention group
Group type: EXPERIMENTAL
Intervention: Emla with suggestions of hyperalgesia
Number of subjects: 142
Study 25599299 — intervention group
Group type: COMPARATOR
Intervention: Placebo with suggestions of analgesia
Number of subjects: 142
Study 25599299 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo with suggestions of hyperalgesia
Number of subjects: 142
Study 25599299 — intervention group
Group type: EXPERIMENTAL
Intervention: Emla with no specific information
Number of subjects: 142
Study 25599299 — intervention group
Group type: COMPARATOR
Intervention: No treatment with pain induction
Number of subjects: 142
Study 23700938 — intervention group
Group type: EXPERIMENTAL
Intervention: Biocompatible PD solutions (CAPDP-2)
Number of subjects: 42
Study 23700938 — intervention group
Group type: COMPARATOR
Intervention: Standard PD solutions (CAPDP-1)
Number of subjects: 42
Study 21881371 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive physical therapy
Number of subjects: 60
Study 21881371 — intervention group
Group type: COMPARATOR
Intervention: Routine physical therapy after operation
Number of subjects: 60
Study 18782649 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3mg/kg body weight)
Number of subjects: 0
Study 18782649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16761153 — intervention group
Group type: EXPERIMENTAL
Intervention: Trilogy Calcicoat (HA/TCP coated)
Number of subjects: 100
Study 16761153 — intervention group
Group type: COMPARATOR
Intervention: Porous coated Trilogy
Number of subjects: 100
Study 15207665 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 800 microg vaginally
Number of subjects: 80
Study 11269453 — intervention group
Group type: EXPERIMENTAL
Intervention: Single aortic cross-clamping technique
Number of subjects: 50
Study 11269453 — intervention group
Group type: COMPARATOR
Intervention: Partial occluding aortic clamp
Number of subjects: 50
Study 10933420 — intervention group
Group type: EXPERIMENTAL
Intervention: Food Frequency Questionnaire (FFQ)
Number of subjects: 13
Study 10933420 — intervention group
Group type: COMPARATOR
Intervention: Food Records
Number of subjects: 13
Study 10933420 — intervention group
Group type: COMPARATOR
Intervention: 24-hour Diet Recalls
Number of subjects: 13
Study 10933420 — intervention group
Group type: COMPARATOR
Intervention: Food Records and 24-hour Diet Recalls
Number of subjects: 13
Study 10933420 — intervention group
Group type: COMPARATOR
Intervention: Analysis of Variance
Number of subjects: 13
Study 10933420 — intervention group
Group type: EXPERIMENTAL
Intervention: Recalls
Number of subjects: 13
Study 7742263 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine ER (FER) 5 mg once daily, increased to 10 mg if necessary
Number of subjects: 98
Study 7742263 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem SR (DSR) 90 mg twice daily, increased to 120 mg if necessary
Number of subjects: 98
Study 2264429 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 41
Study 2264429 — intervention group
Group type: COMPARATOR
Intervention: Sclerotherapy alone (Control)
Number of subjects: 41
Study 35197 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam (dosage ranged from 5 mg daily to 120 mg daily, usual daily dosage in out-patient therapy 20-30 mg)
Number of subjects: 45
Study 35197 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam (dosage ranged from 5 mg daily to 120 mg daily)
Number of subjects: 45
Study 35197 — intervention group
Group type: COMPARATOR
Intervention: Clobazam
Number of subjects: 45
Study 31879231 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous treatment with lysis and stenting
Number of subjects: 11
Study 31664975 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised Packaging (without health warnings)
Number of subjects: 625
Study 31664975 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised Packaging with Health Warnings
Number of subjects: 625
Study 31664975 — intervention group
Group type: COMPARATOR
Intervention: Branded Packaging
Number of subjects: 625
Study 31664975 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised Packaging (both types)
Number of subjects: 625
Study 28608121 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant S-1 with concurrent hypofractionated radiotherapy (30 Gy in 10 fractions, S-1 at 60 mg/m2, 5 days/week for 2 weeks)
Number of subjects: 57
Study 25645170 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive intervention consisting of two sessions of psychoeducation and skills training in reducing accommodation.
Number of subjects: 18
Study 25645170 — intervention group
Group type: COMPARATOR
Intervention: Standard individual exposure and ritual prevention (ERP) for OCD.
Number of subjects: 18
Study 25645170 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in family accommodation from baseline.
Number of subjects: 18
Study 23921928 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverted J‐shaped incision with bony tie‐down suture
Number of subjects: 31
Study 23921928 — intervention group
Group type: COMPARATOR
Intervention: Minimally invasive incision without tie‐down suture
Number of subjects: 31
Study 23921928 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative computed tomography (in 10 patients)
Number of subjects: 31
Study 21241514 — intervention group
Group type: EXPERIMENTAL
Intervention: DECISION+ program (three 3-hour workshops over a four- to six-month period)
Number of subjects: 544
Study 21241514 — intervention group
Group type: COMPARATOR
Intervention: Control group (delayed exposure to the DECISION+ program)
Number of subjects: 544
Study 19259861 — intervention group
Group type: EXPERIMENTAL
Intervention: Exam-room posters designed by the ACS
Number of subjects: 0
Study 19259861 — intervention group
Group type: EXPERIMENTAL
Intervention: Posters plus patient reminder calls from an ACS volunteer
Number of subjects: 0
Study 19259861 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 16680107 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimanual microincision phacoemulsification using WhiteStar technology
Number of subjects: 33
Study 15486569 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 96 mg/day
Number of subjects: 1289
Study 15486569 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 192 mg/day
Number of subjects: 1289
Study 15486569 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 256 mg/day
Number of subjects: 1289
Study 15486569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1289
Study 15486569 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (all doses)
Number of subjects: 1289
Study 11507297 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol 2 (our protocol): 100 microCi (10 microl) Tc‐99m pertechnetate instilled in the outer canthus of the eye using a micropipette with the patient in the supine position under the gamma camera. Dynamic images taken for only 5 minutes.
Number of subjects: 77
Study 11507297 — intervention group
Group type: COMPARATOR
Intervention: Protocol 1 (the current conventional protocol): 50 microl Tc‐99m pertechnetate containing 50 to 100 microCi radioactivity instilled in the inferior fornix or outer canthus of the eye. Dynamic and static images obtained for approximately 15 to 20 minutes.
Number of subjects: 77
Study 9570195 — intervention group
Group type: EXPERIMENTAL
Intervention: HTLf (helper T cells)
Number of subjects: 10
Study 9570195 — intervention group
Group type: EXPERIMENTAL
Intervention: CTLf (cytotoxic T cells)
Number of subjects: 10
Study 9570195 — intervention group
Group type: COMPARATOR
Intervention: Third-party control
Number of subjects: 10
Study 7809641 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist immobilized in neutral flexion‐extension (Group 1)
Number of subjects: 50
Study 7809641 — intervention group
Group type: COMPARATOR
Intervention: Wrist dorsiflexed 20 degrees (Group 2)
Number of subjects: 50
Study 3055950 — intervention group
Group type: EXPERIMENTAL
Intervention: Virucidal nasal tissues (impregnated with malic and citric acids and sodium lauryl sulfate)
Number of subjects: 284
Study 3055950 — intervention group
Group type: COMPARATOR
Intervention: Placebo tissues (saccharin in trial I; mixture including succinic acid in trial II)
Number of subjects: 284
Study 3055950 — intervention group
Group type: EXPERIMENTAL
Intervention: Virucidal nasal tissues
Number of subjects: 284
Study 1093658 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX)
Number of subjects: 90
Study 1093658 — intervention group
Group type: COMPARATOR
Intervention: Sulfamethoxazole (SMX) alone
Number of subjects: 90
Study 31964579 — intervention group
Group type: COMPARATOR
Intervention: LITE (educational intervention with 2 phone calls)
Number of subjects: 614
Study 31964579 — intervention group
Group type: COMPARATOR
Intervention: PLUS (educational intervention with biweekly calls until content competency)
Number of subjects: 614
Study 31964579 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual Care (UC)
Number of subjects: 614
Study 31280079 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD symptom clusters (Negative Alterations in Cognition and Mood and Alterations in Arousal and Reactivity)
Number of subjects: 0
Study 31280079 — intervention group
Group type: EXPERIMENTAL
Intervention: General distress factor
Number of subjects: 0
Study 27465573 — intervention group
Group type: EXPERIMENTAL
Intervention: 27‐gauge (G) pars plana vitrectomy (PPV)
Number of subjects: 30
Study 27465573 — intervention group
Group type: COMPARATOR
Intervention: 25‐G pars plana vitrectomy (PPV)
Number of subjects: 30
Study 23598540 — intervention group
Group type: EXPERIMENTAL
Intervention: High FABP4 concentrations
Number of subjects: 108
Study 23598540 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate FABP4 concentrations
Number of subjects: 108
Study 23598540 — intervention group
Group type: EXPERIMENTAL
Intervention: Low FABP4 concentrations
Number of subjects: 108
Study 23598540 — intervention group
Group type: COMPARATOR
Intervention: Intermediate and high FABP4 concentrations
Number of subjects: 108
Study 23598540 — intervention group
Group type: EXPERIMENTAL
Intervention: FABP4
Number of subjects: 108